GLP1R and type 2 diabetes mellitus: However, some more recent trials included patient populations without previous ASCVD, such as the DECLARE-TIMI 58 (reduction in hospitalization for HF with SGLT2i [16]) and REWIND (MACE reduction with GLP-1 RA [17]) trials, indicating a beneficial preventive effect for DMDs even in earlier stages of type 2 diabetes.